Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Leukemia, Promyelocytic, Acute × vadastuximab talirine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3 Leukemia, Promyelocytic, Acute 1

Interventions

Arsenic Trioxide 3 vadastuximab talirine 1 tamibarotene 1 cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV)) 1 Tretinoin 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Cytarabine 1 Clofarabine 1 AEG 35156 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01902329 2018-01-05

A Safety Study of SGN-CD33A in AML Patients

Seagen Inc.

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡